Hairy Cell Leukemia - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hairy Cell Leukemia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Hairy Cell Leukemia - Pipeline Review, H2 2015', provides an overview of the Hairy Cell Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hairy Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hairy Cell Leukemia Overview 7
Therapeutics Development 8
Pipeline Products for Hairy Cell Leukemia - Overview 8
Hairy Cell Leukemia - Therapeutics under Development by Companies 9
Hairy Cell Leukemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Hairy Cell Leukemia - Products under Development by Companies 14
Hairy Cell Leukemia - Companies Involved in Therapeutics Development 15
AbbVie Inc. 15
Astellas Pharma Inc. 16
AstraZeneca Plc 17
Biogenomics Limited 18
F. Hoffmann-La Roche Ltd. 19
Inbiopro Solutions Pvt. Ltd. 20
Incyte Corporation 21
MedImmune, LLC 22
Novartis AG 23
Hairy Cell Leukemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
(INCB-039110 + INCB-040093) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AGS-67E - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AZD-6738 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
IBPB-006IA - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ibrutinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
INCB-39110 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
INCB-40093 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
INCB-50465 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
interferon alfa-2a - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
interferon alfa-2b - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
interferon alfa-2b - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
moxetumomab pasudotox - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
vemurafenib - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Hairy Cell Leukemia - Recent Pipeline Updates 61
Hairy Cell Leukemia - Dormant Projects 88
Hairy Cell Leukemia - Discontinued Products 89
Hairy Cell Leukemia - Product Development Milestones 90
Featured News & Press Releases 90
May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables

Number of Products under Development for Hairy Cell Leukemia, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Comparative Analysis by Unknown Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Hairy Cell Leukemia - Pipeline by AbbVie Inc., H2 2015 15
Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2015 16
Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, H2 2015 17
Hairy Cell Leukemia - Pipeline by Biogenomics Limited, H2 2015 18
Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 19
Hairy Cell Leukemia - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 20
Hairy Cell Leukemia - Pipeline by Incyte Corporation, H2 2015 21
Hairy Cell Leukemia - Pipeline by MedImmune, LLC, H2 2015 22
Hairy Cell Leukemia - Pipeline by Novartis AG, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Assessment by Combination Products, H2 2015 25
Number of Products by Stage and Target, H2 2015 27
Number of Products by Stage and Mechanism of Action, H2 2015 29
Number of Products by Stage and Route of Administration, H2 2015 31
Number of Products by Stage and Molecule Type, H2 2015 33
Hairy Cell Leukemia Therapeutics - Recent Pipeline Updates, H2 2015 61
Hairy Cell Leukemia - Dormant Projects, H2 2015 88
Hairy Cell Leukemia - Discontinued Products, H2 2015 89